1. Home
  2. SOHU vs CCCC Comparison

SOHU vs CCCC Comparison

Compare SOHU & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sohu.com Limited

SOHU

Sohu.com Limited

SELL

Current Price

$12.54

Market Cap

324.6M

Sector

Technology

ML Signal

SELL

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

SELL

Current Price

$3.06

Market Cap

350.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SOHU
CCCC
Founded
1996
2015
Country
China
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
324.6M
350.6M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
SOHU
CCCC
Price
$12.54
$3.06
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
8
Target Price
★ $19.50
$12.86
AVG Volume (30 Days)
84.9K
★ 2.0M
Earning Date
11-16-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 16.45
EPS
★ N/A
N/A
Revenue
N/A
★ $35,947,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2.46
N/A
P/E Ratio
$1.16
★ N/A
Revenue Growth
N/A
★ 1.02
52 Week Low
$11.61
$1.69
52 Week High
$17.30
$5.17

Technical Indicators

Market Signals
Indicator
SOHU
CCCC
Relative Strength Index (RSI) 39.14 44.23
Support Level $12.41 $2.88
Resistance Level $13.71 $3.20
Average True Range (ATR) 0.36 0.22
MACD -0.01 0.02
Stochastic Oscillator 25.51 54.54

Price Performance

Historical Comparison
SOHU
CCCC

About SOHU Sohu.com Limited

Sohu.com Ltd provides online media, games, and search products and services on PCs and mobile devices in China. The company operates in Sohu and Changyou segments. Sohu is an online media content and services provider. Through its social features, Sohu also enables users to generate and distribute content, as well as interact with each other on a platform. Changyou is an online game developer and operator. It generates maximum revenue from the Changyou segment.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Share on Social Networks: